Skip To Main Content
Maher Hanoun on Muck Rack

Maher Hanoun

As seen in: Nature, Cell Press, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maher

Contact Maher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients - Leukemia

|
By Marius Bill, Jan-Niklas Eckardt, Christian Rausch, Klaus H. Metzeler, Karsten Spiekermann, Sebastian Stasik, Alexander A. Wurm, Ulf Schnetzke, Andreas Hochhaus Verified, Bernhard Wörmann, Hermann Einsele, Dennis Görlich, Andreas Burchert, Christoph Schliemann, Stefan Krause, Maher Hanoun, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas Thol, Claudia D. Baldus, Carsten Müller-Tidow, Jan Valka, Barbora Weinbergerova, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Maximillian-Alexander Röhnert
| Nature Verified
Open in Who Shared Issue with article?

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition

|
By Eli L. Diamond, Jean-François Emile, Takeshi Fujino, Julien Haroche, Maxim I. Maron, Alexander Lewis Verified, Jahan A. Rahman, Anne Reiner, Dana F. Bossert, Marc K. Rosenblum, Mariko Yabe, Kseniya Petrova-Drus, Jasmine H. Francis, Veronica Rotemberg, Raajit Rampal, Sarah Paiji Yoo, Anthony F. Daniyan, sonia mahajan, Vaios Hatzoglou, Robert Young, Gary A. Ulaner, Wiebke Rösler, Oshrat Hershkovitz-Rokah, Ofer Shpilberg, Roei D. Mazor, Michael Singer Verified, M. Adriana Cuibus, Salima Benbarche, Pu Zhang, Nina Fox, Cynthia Castro, Matthew Witkowski, Fleur Cohen-Aubart, Louis Terriou, Maher Hanoun, Nicolas Schleinitz, Gabriela Sosa, Timo Hautala, Neal Rosen, Omar Abdel-Wahab Verified, Benjamin H. Durham, Kenyon Weis, Steven Tittley
| Cell Press Verified
Open in Who Shared Issue with article?

Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients - Blood Cancer Journal

|
By Jan Moritz Middeke, Christoph Röllig, Matthias Stelljes, Verena I. Gaidzik, Katrin Koch, Felicitas Thol, Stefan Krause, Vladan Vucinic, Michael Heuser, Guido Kobbe, Nael Alakel, Malte von Bonin, Katja Sockel, Maher Hanoun, Katharina Götze, Eva Wagner-Drouet, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Thomas Schroeder, Charlotte Neuerburg, Sara Flossdorf
| Nature Verified
Although the pivotal phase-3 trial establishing CPX-351 as standard of care for therapy-related AML (tAML) or AML with myelodysplasia-related changes (AML-MRC) was performed only in patients aged 60–75 years [1, 2], it is approved for adults without age limit. Still, limited data resulted in restrictive recommendations regarding its use in younger patients (<60 years) by national and international guidelines [3].
Open in Who Shared Issue with article?
See all 11 articles